Prevention of Attacks of Hereditary Angioedema (HAE) with Subcutaneous C1-Esterase Inhibitor (C1-INH [SC]) by Anatomical Location: Results From the Phase III COMPACT Study (NCT01912456)

Rationale Subcutaneous C1-INH (HAEGARDA®, CSL Behring, Marburg) at 60 IU/kg was recently approved by the US FDA as routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescents and adults, based on the COMPACT study. Methods In the COMPACT study, 45 patients self-administered C1-...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 141; no. 2; p. AB45
Main Authors Levy, Donald S., Chiao, Joseph, Feuersenger, Henrike, Craig, Timothy, Longhurst, Hilary J., Cicardi, Marco, Zuraw, Bruce L., Jacobs, Iris
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Inc 01.02.2018
Elsevier Limited
Subjects
Angioedema
Edema
Esterase
United States > US
Online AccessGet full text

Cover

More Information
Summary:Rationale Subcutaneous C1-INH (HAEGARDA®, CSL Behring, Marburg) at 60 IU/kg was recently approved by the US FDA as routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescents and adults, based on the COMPACT study. Methods In the COMPACT study, 45 patients self-administered C1-INH (SC) 60 IU/kg body weight or placebo twice weekly in a double-blind, crossover manner over two 16-week treatment periods.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.148